Clinical trials: Decreased Vascular Flow
Coronary Artery Disease
Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion
The MARKOV study is an investigator-sponsored single arm, prospective study to assess the effect of evolocumab on the improvement in coronary flow (FFRCT) after 18 and 36 months of treatment in patients with coronary…
- Trial name
- MARKOV (NCT03851263)
- Testing
- Evolocumab
- Sponsor
- ECRI bv
Refractory Angina Pectoris, Ischemic Heart Disease
Cardiac Shock Wave Treatment in Patients With Reduced Coronary Flow Reserve
The purpose of the study is to assess the feasibility of Cardiac Shock Wave Treatment in patients with anginal chest pain and evidence of abnormal myocardial perfusion under stress in the absence of significant stenoses of the…
- Conditions
- Refractory Angina Pectoris, Ischemic Heart Disease, Coronary Artery Disease
- Trial name
- NCT03438500
- Testing
- Cardiac Extracorporeal Shockwave Therapy (Modulith SLC)
- Where
- Germany
- Sponsor
- Storz Medical AG
Ischemic Stroke
Augmenting Cerebral Blood Flow to Preserve the Penumbra Trial
The primary objective of the study is to demonstrate that SPG (Sphenopalatine Ganglion) stimulation started within 6 hours from stroke onset slows the expansion of the infarct core volume in acute ischemic stroke.
- Trial name
- ImpACT-P (NCT04014621)
- Testing
- SPG stimulation
- Where
- 4 sites in Georgia
- Volunteers
- 100 people
- Sponsor
- BrainsGate
Periferal Arterial Occlusive Disease, PAOD
Effect on Blood Flow Using the FlowOx™ Device in Patients With Reduced Peripheral Circulation in the Lower Leg
A study to assess the effect of negative pulsating pressure therapy on patients with impaired blood flow to the leg caused by arterial disease, to see if the FlowOx device will increase the blood flow to the leg in these patients.
- Trial name
- NCT01893840
- Testing
- FlowOx
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Otivio AS
Heart Failure
Study to Evaluate the Effects of AZD3427 in Patients With Heart Failure
The primary purpose of this mechanistic study is to evaluate the vasodilatory effects of AZD3427 in adult patients with heart failure and will be performed at approximately 2 study sites in the United Kingdom.
- Trial name
- NCT04890548
- Testing
- AZD3427
- Sponsor
- AstraZeneca
Prevention of Atherothrombotic Events, Coronary Artery Disease (CAD)
Study to Learn More About the Safety and Effectiveness of Rivaroxaban (Xarelto) When Given Together With Acetylsalicylic Acid to Indian People With Narrowing of the Arteries of the Heart (CAD) and/or With Reduced Blood Flow in the Arteries of the Legs and Arms With Symptoms (Symptomatic PAD)
This is an observational study in which data from Indian people with coronary artery disease and / or symptomatic peripheral artery disease who will be receiving the drug rivaroxaban (Xarelto) are studied.
- Conditions
- Prevention of Atherothrombotic Events, Coronary Artery Disease (CAD), Symptomatic Peripheral Artery Disease (Symptomatic PAD)
- Trial name
- NCT04298567
- Testing
- Rivaroxaban (Xarelto,Bay 59-7939), Acetylsalicylic acid(ASA)
- Where
- India
- Volunteers
- 300 people
- Sponsor
- Bayer
Heart Failure With Reduced Ejection Fraction
Lumacaftor Yields Reversal of Impaired Cerebral Blood Flow in Heart Failure Patients
Cognitive impairment (CI) is highly prevalent in patients with heart failure with reduced ejection fraction (HFrEF), which has significant implications for disease management, quality of life and clinical outcomes.
- Trial name
- LYRIC-HF (NCT07695090)
- Testing
- Lumacaftor 200 MG
- Where
- 2 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Qanatpharma AG